Anti-adrenergic therapy has been widely accepted as an important therapeutic intervention in patients with chronic heart failure. However, there has been continuing controversy regarding the risks and clinical significance of metabolic effects of different anti-adrenergic drugs. This review summarizes what has been learned from clinical trial evidence regarding the benefits of anti-adrenergic drugs in diabetic patients with chronic heart failure

Wilson Tang, WH

English

PubMed

WH Wilson TangSection of Heart Failure and Cardiac Transplantation Medicine, Department of Cardiovascular Medicine, the Cleveland Clinic, Cleveland, OH, USAAbstract: Anti-adrenergic therapy has been widely accepted as an important therapeutic intervention in patients with chronic heart failure. However, there has been continuing controversy regarding the risks and clinical significance of metabolic effects of different anti-adrenergic drugs. This review summarizes what has been learned from clinical trial evidence regarding the benefits of anti-adrenergic drugs in diabetic patients with chronic heart failure.Keywords: diabetes mellitus, congestive heart failure, anti-adrenergic drugs, carvedilo

WH Wilson Tang

Directory of Open Access Journals

Vascular Health and Risk Management

A critical review of anti-adrenergic therapy in patients with heart failure and diabetes mellitus

After myocardial infarction carvedilol improves insulin resistance compared to metoprolol. Clin Res Cardiol,

Are beta-blockers as efﬁ cacious in patients with diabetes mellitus as in patients without diabetes mellitus who have chronic heart failure? A meta-analysis of large-scale clinical trials.

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.

Association of poor glycemic control with prolonged hospital stay in patients with diabetes admitted with exacerbation of congestive heart failure. Endocr Pract,

Cardiomyopathy and heart failure in diabetes.

Carvedilol does not alter the insulin sensitivity in patients with congestive heart failure.

Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET.

Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.

Diabetes and cardiovascular disease. The Framingham study.

Diabetes in heart failure: prevalence and impact on outcome in the population.

Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: the carvedilol-metoprolol study.

Differentiation of the metabolic and vascular effects of insulin in insulin resistance in patients with chronic heart failure.

Does carvedilol impair insulin sensitivity in heart failure patients without diabetes.

Effect of beta-blockers on insulin resistance in patients with dilated cardiomyopathy.

Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure:data from the Carvedilol Or Metoprolol European Trial (COMET).

Efﬁ cacy of angiotensinconverting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials.

Efﬁ cacy, safety and tolerability of metoprolol CR/XL in patients with diabetes and chronic heart failure: experiences from MERIT-HF. Am Heart J,

Glycemic control and heart failure among adult patients with diabetes.

Glycemic control and treatment patterns in patients with heart failure. Heart Fail Monit,

Inﬂ uence of carvedilol on blood glucose and glycohaemoglobin A1 in non-insulin-dependent diabetics.

Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure.

Insulin resistance in idiopathic dilated cardiomyopathy: a possible etiologic link. J Am Coll Cardiol,

Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension.A randomized, controlled trial.

Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.

Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction.

Relationship between tumor necrosis factor-alpha production and oxidative stress in the failing hearts of patients with dilated cardiomyopathy.

Results from post-hoc analyses of the CIBIS II trial: effect of bisoprolol in high-risk patient groups with chronic heart failure.

Should physicians avoid the use of beta-blockers in patients with heart failure who have diabetes?

The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy. Cardiovasc Res,

The effect of carvedilol on mortality risk in heart failure patients with diabetes: results of a metaanalysis. Curr Med Res Opin,

The effect of diabetes on outcomes of patients with advanced heart failure in the BEST trial.

The effects of combined versus selective adrenergic blockade on left ventricular and systemic hemodynamics, myocardial substrate preference, and regional perfusion in conscious dogs with dilated cardiomyopathy.

The metabolic vicious cycle in heart failure.

The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and nondiabetic participants in the HOPE study: a prospective epidemiological analysis.

Vascular endothelial dysfunction and mortality risk in patients with chronic heart failure.

Vascular Health and Risk Management 2007:3(5) 645 Anti-adrenergic therapy in diabetic heart failure

http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2291308

A critical review of anti-adrenergic therapy in patients with heart failure and diabetes mellitus

Abstract

Similar works

Full text

Available Versions

Directory of Open Access Journals